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Abstract
The development and maintenance of skeletal muscle and bone mass is critical for movement, 
health and issues associated with the quality of life. Skeletal muscle and bone mass are regulated 
by a variety of factors that include changes in mechanical loading. Moreover, bone mass is, in 
large part, regulated by muscle-derived mechanical forces and thus by changes in muscle mass/
strength. A thorough understanding of the cellular mechanism(s) responsible for 
mechanotransduction in bone and skeletal muscle is essential for the development of effective 
exercise and pharmaceutical strategies aimed at increasing, and/or preventing the loss of, mass in 
these tissues. Thus, in this review we will attempt to summarize the current evidence for the major 
molecular mechanisms involved in mechanotransduction in skeletal muscle and bone. By 
examining the differences and similarities in mechanotransduction between these two tissues, it is 
hoped that this review will stimulate new insights and ideas for future research and promote 
collaboration between bone and muscle biologists.
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INTRODUCTION
Skeletal muscle and bone play fundamental roles in human physiology, enabling locomotion 
and movement, enhancing blood flow to organs, and providing protection to vital organs, 
among others. Beyond the mechanical roles of these two organ systems, both are also major 
regulators of whole body metabolism. For instance, skeletal muscle serves as a storage site/
consumer of amino acids and glucose, and secretes various myokines that affect metabolism 
in other tissues [1–3]. Bone serves as an ion bank for maintaining serum levels of 
physiologically crucial elements such as Ca2+ and Mg2+, and also secretes active endocrine 
products [4–6]. In light of the far-reaching roles of these tissues in general health, it is 
imperative that the field comes to a better understanding of the conditions that 
concomitantly affect muscle and bone health, most notably reduced bone and/or skeletal 
muscle mass (either during pre/post-natal development or in adults). These conditions have 
the potential to increase the risk of injury and metabolic disease, reduce physical mobility, 
and ultimately affect the quality and duration of life.
Skeletal muscle mass and bone mass are regulated by a range of factors that include 
genetics, nutrition, hormones and growth factors and, in particular, mechanical stimuli [7, 
8]. It is well known that an increase in mechanical loading of skeletal muscle results in an 
increase in skeletal muscle mass (i.e., muscle hypertrophy), while a decrease in mechanical 
loading leads to a reduction of skeletal muscle mass (i.e., muscle atrophy) (for reviews see 
[9–11]). The mechanical loading experienced by skeletal muscle typically comprises the 
internal longitudinal and lateral forces, of varying magnitudes and velocities, which are 
generated by active muscle contractions (e.g., shortening, lengthening, or isometric 
contractions) or by passive stretch. Changes in mechanical loading are also known to play a 
major role in the regulation of bone mass and strength; increased mechanical loading at 
critical stages of growth and development result in increased bone mineral accrual, bone 
mass and strength, while reduced mechanical loading results in the loss of bone mass and 
strength (for reviews see [12–14]). Importantly, evidence suggests that the development and 
maintenance of bone mass is, in large part, dependent on skeletal muscle-derived 
mechanical loading [15, 16].
Skeletal muscles contribute to the mechanical loading of bone in various ways that include 
the tensile forces developed by contracting muscles at their site of insertion, the compressive 
forces between bones developed by muscles contracting across joints, and bending forces 
experienced by long bones as muscles generate force for lifting distally held objects [15]. In 
support of a critical role for skeletal muscle-induced mechanical stimuli in the regulation of 
bone mass, studies have shown that a lack of muscle function in utero results in impaired 
fetal bone and joint development [17–21]. Furthermore, during post-natal skeletal growth 
(2–20 yr), there is a very strong positive correlation between muscle mass and bone mass, 
with gains in muscle mass preceding those in bone mass [22]. In fact, the associations 
between muscle/strength and bone mass in children are strong enough that clinical 
techniques for disease diagnosis can be founded upon them [23, 24]. For instance, 
deficiencies in the amount of bone per unit muscle strength versus deficiencies in both 
factors allow for classification of diagnoses into primary (true or intrinsic) and secondary 
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(physiologic) bone disorders. Combined, these data strongly suggest that greater forces, 
produced by larger muscles, may play a direct role in stimulating bone growth. Conversely, 
states of reduced muscle mass and function, such as various neuromuscular diseases (e.g. 
cerebral palsy and Duchenne muscular dystrophy [25, 26]), spinal cord injury [27] and space 
flight [28], are all associated with a loss of bone mass. It is also interesting to note, and 
perhaps telling with respect to the influence of muscle forces on bone mass, that in many 
disease states, bone mass is typically not over adapted for muscle mass [29].
Despite the fundamental dependence on mechanical stimuli for the development and/or 
maintenance of bone and skeletal muscle mass, the exact mechanism(s) by which changes in 
mechanical loading are transduced into anabolic or catabolic signaling events (i.e, 
mechanotransduction) in these tissues remains to be fully determined. A thorough 
understanding of the cellular mechanism(s) responsible for mechanotransduction in bone 
and skeletal muscle is essential for the development of effective exercise and pharmaceutical 
strategies aimed at increasing, and/or preventing the loss of, mass in these critical tissues. 
Furthermore, it is clear that a sizeable and powerful complement of skeletal muscle and a 
robust and rigid skeleton are desirable outcomes for optimal connective tissue health. 
Therefore, it is worthwhile to understand the molecular underpinnings of 
mechanotransduction in both tissues and to determine whether both can be optimized in 
tandem [30]. Hence, the purpose of this review is to summarize our understanding of the key 
mechano-sensitive signaling events that are thought play a role in the regulation of bone and 
skeletal muscle mass. Importantly, we will also highlight important gaps in the body of 
knowledge in the hope that this will stimulate further research, and potentially collaboration 
between bone and muscle biologists.
MECHANOTRANSDUCTION AND THE REGULATION OF SKELETAL 
MUSCLE MASS
Skeletal muscle mass is ultimately determined by the net difference in the rates of protein 
degradation and protein synthesis [31]. For example, a net increase in protein synthesis 
and/or a net decrease in protein degradation leads to muscle hypertrophy, while a net 
decrease in protein synthesis and/or increase in protein degradation results in muscle 
atrophy. Importantly, mechanical load-induced changes in muscle mass are associated with 
changes in protein synthesis, with increased mechanical load-induced muscle hypertrophy 
being associated with an increase in protein synthesis [10]. Despite the major role that 
protein synthesis plays in the mechanical regulation of skeletal muscle mass, the molecular 
mechanism(s) through which changes in mechanical loading regulate protein synthesis, and 
thus muscle mass, remain to be fully determined. Nevertheless, progress is being made and a 
significant body of evidence now indicates that the protein kinase called the mechanistic/
mammalian target of rapamycin (mTOR) plays a central role in the pathway through which 
mechanical stimuli regulate protein synthesis and muscle mass [9, 11]. As such, the 
remainder of this section will focus on the role of mTOR in mechanically-induced increases 
in protein synthesis and muscle mass, and on several putative mechanically-sensitive factors 
that are proposed to play a role in the activation of mTOR signaling. It is important to note, 
however, that other signaling mechanisms also play important roles in the regulation of 
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protein synthesis and skeletal muscle mass during different stages of growth and 
development and under various conditions that may include increased mechanical loading 
[for recent reviews on these topics, see [32–41]. Furthermore, although somewhat 
controversial, there is also evidence that proliferation, differentiation and fusion of satellite 
cells (SC) may play a role in the mechanical regulation of skeletal muscle mass; however, 
the exact mechanism(s) responsible for the mechanically-induced activation of SCs remains 
to be determined [10, 42–45].
The Central Role of mTOR/mTORC1 in Mechanically-Induced Skeletal Muscle Growth
mTOR is a conserved serine/threonine kinase that is found in at least two multi-protein 
complexes: mTOR complex 1 (mTORC1), whose signaling is partly inhibited by the drug 
rapamycin, and mTORC2, which is largely rapamycin-resistant [46]. mTORC1 is a major 
regulator of cell growth, in part, by regulating mRNA translation, and thus protein synthesis, 
with the potential to regulate both translational efficiency (i.e., the rate of mRNA 
translation) and translational capacity (i.e., the number of ribosomes) (for a review, see 
[47]). Importantly, in skeletal muscle, mTORC1 signaling has been shown to be activated by 
a wide-range of different types of mechanical stimuli, and this effect can be observed in cell 
culture, and in whole muscle ex vivo and in vivo model systems [9]. Moreover, it has been 
demonstrated that the in vivo activation of mTORC1 signaling is sufficient to stimulate an 
increase in protein synthesis and induce muscle fiber hypertrophy [48, 49], and that the 
kinase activity of mTOR is necessary for mechanical load-induced muscle hypertrophy [50, 
51]. However, despite the robust evidence for mTORC1’s central role in mechanically-
induced skeletal muscle growth, the identification of the upstream mechanism(s) that are 
responsible for the mechanical activation of mTORC1 remains a significant challenge. 
Below we will briefly describe the evidence for, and against, several putative mechanically-
induced activators of mTORC1 signaling in skeletal muscle
Potential Candidates for the Mechanically-Induced Activation of mTORC1
Insulin-Like Growth Factor 1—One of the earliest molecules that was proposed to be 
involved in the mechanical activation of mTORC1 signaling is the insulin-like growth factor 
1 (IGF-1). For example, early studies showed that IGF-1 expression was increased by 
mechanical loading, including a splice variant known as the mechano growth factor (MGF) 
which was proposed to act in an autocrine manner [52–55]. IGF-1 overexpression was also 
shown to be sufficient to activate PI3K/Akt/mTORC1 signaling, increase protein synthesis 
and induce muscle hypertrophy [56–65]. While there is some limited evidence that IGF-1 
may play a role in the increase in protein synthesis several hours after resistance exercise in 
diabetic muscle [66], more recently, a significant body of evidence has accumulated which 
indicates that mechanical stimuli activate mTORC1 signaling, at least initially, via an IGF-1/
PI3K/Akt-independent mechanism, and that IGF-1/PI3K/Akt signaling is not necessary for 
mechanically-induced skeletal muscle growth (for a more detailed review of this topic see 
[9]). Thus, while IGF-1 plays an important role in the development and/or maintenance of 
skeletal muscle mass [67], current evidence suggests that IGF-1 does not play a significant 
role in the acute mechanical activation of mTORC1 and that IGF-1 is not necessary for 
mechanically-induced skeletal muscle hypertrophy. Further work is required to definitively 
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determine the role, if any, of IGF-1 in the acute and more prolonged activation of mTORC1 
and protein synthesis, and in muscle hypertrophy, in response to mechanical stimuli.
Extracellular Signal-Regulated Kinase 1 and 2—Another potential mechanically-
activated upstream regulator of mTORC1 and skeletal muscle mass is the extracellular 
signal–regulated kinases 1 and 2 (ERK1/2). These members of the mitogen-activated protein 
kinase (MAPK) family form part of the Ras/Raf/MEK/ERK1/2 signaling pathway and are 
activated by various types of mechanical stimuli in cultured muscle cells and in rodent and 
human skeletal muscle in vivo [68–74]. ERK1/2-mediated signaling has the potential to 
positively regulate protein synthesis, in part, by the activation of mTORC1 signaling via 
p90RSK-mediated phosphorylation of TSC2 and Raptor [75–80]. While these studies 
suggest that ERK1/2 signaling could play a role in the mechanical activation of mTORC1 
signaling, protein synthesis, and muscle hypertrophy, it was recently shown that ERK1/2 
inhibition does not prevent stretch-induced hypertrophy in cultured myotubes [71]. 
Furthermore, while inhibition of ERK1/2 reduced basal mTORC1 signaling, it did not 
inhibit the stretch-induced increase in mTORC1 signaling or protein synthesis in isolated 
mouse muscles [74]. Thus, based on a limited number of studies, it appears that ERK1/2 
signaling is not necessary for the mechanically-induced activation of mTORC1 signaling, 
protein synthesis, or muscle hypertrophy. Further research in rodents and humans, using 
different experimental models, is needed to further clarify these findings.
Phosphatidic Acid—In the absence of convincing evidence for either IGF-1 or ERK1/2 
in the mechanical activation of mTORC1, protein synthesis or skeletal muscle growth, 
recent studies have begun to focus on the glycerophospholipid second messenger, 
phosphatidic acid (PA). PA is a direct activator mTORC1 signaling, most likely via its 
ability to bind to the FKBP12-rapamycin binding (FRB) domain of mTOR [74, 81, 82]. 
Studies have shown that the stimulation of cells with exogenous PA, or the overexpression 
of PA-generating enzymes, such as phospholipase D1 (PLD1), lysophosphatidic acid 
acyltransferase θ (LPAATθ) and diacylglycerol kinase ζ (DGKζ), activates mTORC1 
signaling [74, 83–86]. Furthermore, the overexpression of PLD1 and DGKζ has been shown 
to be sufficient to induce skeletal muscle fiber hypertrophy in mice [87, 88]. Importantly, 
mechanical stimulation of skeletal muscle (i.e. passive stretch and eccentric contractions) 
induces an increase in muscle [PA] [74, 85, 88], suggesting that PA could indeed play a role 
in the mechanical activation of mTORC1. Initial studies investigating this hypothesis 
focused on the potential role of PLD as the source for the mechanically-induced increase in 
PA [85, 89]; however, more recent studies using a specific small-molecule PLD inhibitor 
found that PLD activity was not necessary for passive stretch-induced increases in PA [88]. 
Instead, it was found that passive stretch induced an increased in membrane associated DGK 
activity. Furthermore, in DGKζ knockout mice, it was shown that the stretch-induced 
increase in PA is almost completely abolished and that the activation of mTORC1 signaling 
is markedly impaired [74]. Thus, current evidence strongly suggests that DGKζ is 
predominantly responsible for the stretch-induced increase in PA and is a major contributor 
to the mechanical activation of mTORC1 signaling. Further research is still required, 
however, to confirm the role of DGKζ in other models of mechanical stimulation (e.g. 
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eccentric contractions and synergist ablation-induced mechanical overload) and to determine 
whether DGKζ-derived PA is sufficient to increase protein synthesis.
TSC2 Translocation and Rheb GTP-Loading Status—TSC2 and Rheb (Ras 
homologue enriched in the brain) form part of the canonical insulin/IGF-1 signaling 
pathway [90]. Rheb, located immediately upstream of mTOR, is a GTP-binding protein that 
possesses GTPase activity and its GTP/GDP-binding status is regulated by the GTPase 
activating protein (GAP) activity of TSC2 (a.k.a. Tuberin) [91]. Rheb interacts with 
mTOR’s catalytic domain, and when in its GTP-bound state, Rheb can directly activate 
mTOR kinase activity [92, 93]. It is currently thought that, under basal conditions, the GAP 
domain of TSC2 stimulates Rheb’s intrinsic GTPase activity which converts active GTP-
Rheb into inactive GDP-Rheb, and thus leads to a repression of mTORC1 signaling [94–96]. 
Conversely, when stimulated by factors such as insulin, TSC2 GAP activity is proposed to 
be inhibited in a phosphorylation-dependent manner, leading to an increase in GTP-Rheb 
and the activation of mTORC1 signaling [90]. In skeletal muscle, the overexpression of 
Rheb is sufficient to activate mTORC1 signaling, induce an increase in protein synthesis, 
and stimulate muscle fiber hypertrophy [48, 49]. Despite this, there is currently very little 
known about the potential role of TSC2 and Rheb in the mechanical activation of mTORC1 
signaling in skeletal muscle. Recently, however, it was shown that an acute bout of eccentric 
contractions almost completely abolished the association of TSC2 with late endosomal/
lysosomal (LEL) structures [97]. As LEL structures are also the location of a population of 
mTOR and Rheb (for review see [98]), this finding suggests that the mechanically-induced 
translocation of TSC2 away from the LEL could lead to an increase in the amount of GTP-
loaded Rheb at the LEL and subsequently promote the activation of mTORC1 signaling. 
While these findings appear promising, it remains to be determined whether: 1) the 
translocation of TSC2 away from the LEL plays an important role in the mechanical 
activation of mTORC1 signaling; 2) whether TSC2 translocation is mediated through a 
phosphorylation-mediated event and, if so, what kinase(s) are responsible for the changes in 
TSC2 phosphorylation; and 3) whether Rheb is necessary for the mechanical activation of 
mTORC1 signaling, protein synthesis and hypertrophy.
Increased Intracellular Calcium—Skeletal muscle contractions are initiated by an 
action potential-induced release of calcium (Ca2+) from the sarcoplasmic reticulum (SR) and 
the subsequent Ca2+-induced activation of the contractile apparatus [99]. Furthermore, 
passive stretch of myoblasts and skeletal muscles can also result in an increase in 
intracellular Ca2+ ([Ca2+]i), most likely via the activation of stretch sensitive ion channels 
[100, 101]. Importantly, studies in non-muscle cells have shown that mTORC1 signaling 
may be regulated by changes in [Ca2+]i, with an increase in [Ca2+]i activating mTORC1 
signaling and a decrease in [Ca2+]i leading to an inhibition of mTORC1 signaling [102, 
103]. Increased [Ca2+]i has also been shown to increase ex vivo rates of protein synthesis in 
resting skeletal muscle [104]. Thus, contraction- or stretch-induced increases in [Ca2+]i 
would appear to be an ideal candidate for the mechanical activation of mTORC1 and protein 
synthesis in skeletal muscle. However, despite the potential role for [Ca2+]i, few studies 
have attempted to directly examine this hypothesis. Firstly, it was reported that the Ca2+ 
chelator, BAPTA-AM, did not inhibit ex vivo stretch-induced mTORC1 signaling in isolated 
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skeletal muscles [89]. In contrast, the in vivo inhibition of Ca2+ (and Na+) permeable stretch-
activated ion channels with gadolinium (Gd3+) was shown to inhibit the eccentric 
contraction-induced increase in [Ca2+]i and Gd3+ attenuated eccentric contraction-induced 
mTORC1 signaling [105, 106]. More recently, it was shown that the in vivo mechanical 
overload-induced activation of mTORC1 signaling and muscle hypertrophy was stimulated 
by an increase in [Ca2+]i via the activation of SR transient receptor potential cation channel 
subfamily V (TrpV1) channels [107, 108]. Mechanistically, a contraction/stretch-induced 
increase in [Ca2+]i could potentially stimulate mTORC1 signaling and protein synthesis by 
the activation of the Ca2+/calmodulin-dependent protein kinase α (CaMKKα) which has 
been shown to up regulated by chronic mechanical overload [109, 110]. Furthermore, 
constitutively active CaMKKα was found to be sufficient to activate mTORC1 signaling, 
increase protein synthesis in a rapamycin-sensitive manner and induce muscle hypertrophy; 
however, paradoxically CaMKKα was also found to not be necessary for overload-induced 
muscle growth [110]. Thus, overall, while increases in [Ca2+]i are an attractive candidate for 
the mechanical activation of mTORC1, further work is required to reconcile some of the 
conflicting results obtained to date, and to identify the molecular mechanism(s) through 
which changes in [Ca2+]i could regulate mTORC1 signaling.
Reactive Nitrogen Species—Studies in non-muscle cells have shown that mTORC1 
signaling can be regulated positively and negatively by changes in the cellular redox state 
[111]. It is well known that the acute mechanical stimulation of skeletal muscle results in 
changes in the cellular redox state via the production of reactive oxygen species [ROS; e.g., 
superoxide (O2−) and hydrogen peroxide (H2O2)] and reactive nitrogen species [RNS; e.g., 
nitric oxide (NO) and peroxynitrite (ONOO−)] [112]. Therefore, changes in the production 
of ROS and/or RNS are potential candidates for the mechanical activation of mTORC1 
signaling and skeletal muscle hypertrophy. In support of this possibility, it has been shown 
that the nitric oxide synthase (NOS) inhibitor, L-NAME, can inhibit stretch-induced 
hypertrophy of cultured myotubes and synergist ablation-induced muscle hypertrophy in rats 
[113–115]. Furthermore, muscles from neuronal NOS (nNOS)-null mice fail to undergo 
synergist ablation-induced muscle hypertrophy [107]. The exact mechanism behind the 
apparent role of NO in mechanically-induced hypertrophy remains to be determined, but 
recent evidence suggests that it may, in part, be due to increases in [Ca2+]i [107]. 
Specifically, it was concluded that the synergist ablation-induced increase in [Ca2+]i and 
mTORC1 signaling is stimulated by the formation of ONOO− that is produced from nNOS-
derived NO and NADPH oxidase 4 (Nox4)-derived O2− [107, 108]. Although very 
attractive, significantly more work using different experimental models will be required to 
fully define the role of RNS in the mechanical activation of mTORC1 and skeletal muscle 
growth. Interestingly, nNOS-derived NO may also play a role in muscle atrophy induced by 
a reduction in mechanical loading [116]. For example, it was recently shown that hindlimb 
suspension-induced muscle atrophy was associated with the dislocation of nNOS from the 
membrane associated dystrophin glycoprotein complex to the cytoplasm and with increased 
NO production. Furthermore, the muscle atrophy was inhibited in nNOS-null mice and in 
mice treated with the nNOS-specific inhibitor, 7-nitroindazole [116]. Thus, RNS appear play 
a role in the regulation of muscle mass in response to both increased and decreased 
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mechanical loading. Further work is required to determine whether there is any link between 
muscle atrophy, NO and mTORC1 signaling.
Amino Acids—Amino acids are well known regulators of mTORC1 signaling, with amino 
acid depletion reducing mTORC1 signaling and increased amino acid availability leading to 
increased mTORC1 signaling [117]. It was recently demonstrated in non-muscle cells that 
amino acids regulate the association of mTOR with LEL structures via a mechanism that is 
dependent on the Rag family of GTPases [118–120]. Specifically, amino acid stimulation 
increases the association of mTOR with LEL structures by regulating the activity/GTP-
loading state of the Rag GTPases [121]. Based on these data, it has been suggested that 
amino acid–induced changes in mTORC1 signaling are primarily regulated by spatially 
controlling the ability of mTOR to interact with the LEL-associated activator, Rheb. In 
skeletal muscle, amino acids (especially the branched-chain amino acid, leucine) are 
sufficient to activate mTORC1 signaling and increase protein synthesis via a rapamycin-
sensitive mechanism [122, 123]. Therefore, it is plausible that an increase in the uptake of 
amino acids could play a role in the mechanical activation of mTORC1 signaling. To date, 
however, there is currently no direct evidence to support this hypothesis. Nevertheless, 
recent studies have shown that acute resistance exercise increases both mTORC1 signaling 
and the content of leucine in rat muscle [124], and increases the post-exercise activity of the 
class III PI3K, Vps34, which has been implicated in the amino acid–induced activation 
mTORC1 signaling [125–128]. On the contrary, a recent study has reported a decrease in 
endogenous muscle leucine content after acute resistance exercise despite an increase in 
mTORC1 signaling in middle aged humans [129]. Thus, while some indirect evidence 
suggests that amino acids could play a role in the mechanical activation of mTORC1 
signaling, significantly more research is required to gain further insights into this possibility.
In summary, a significant body of evidence has established that mTORC1 plays a central 
role in the mechanical regulation of protein synthesis and skeletal muscle mass. Currently, 
there are several potential candidate molecules that have been proposed to play a role in the 
pathway through which mechanical stimuli activate mTORC1 signaling. While most of 
these molecules are likely to play important roles in the regulation mTORC1 signaling, 
protein synthesis and muscle mass during different stages of growth and development, 
current evidence suggests that DGKζ-derived PA plays a major role in the acute mechanical 
activation of mTORC1. This role, however, is not necessarily exclusive. Indeed, future 
research may identify that a complex range of factors contribute to the full mechanical 
activation of mTORC1 signaling. For example, the mechanically-induced dissociation of 
TSC2 from the LEL and the subsequent activation of Rheb, an increase in intracellular 
amino acids, and/or RNS-induced SR Ca2+ release may all combine with DGKζ-derived PA 
to promote the full activation of mTORC1 signaling. Ultimately, the relative contribution of 
each activating factor is likely to be specific to the type, intensity and duration of the 
mechanical stimulus, and to the time point examined following the initiation of the stimulus. 
This potential complexity highlights how limited our current understanding is, and 
underscores the need for further research into the process of mechanotransduction on 
regulation of mTORC1, protein synthesis and skeletal muscle mass. Furthermore, 
significantly more research is required to identify the upstream mechano-sensitive 
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element(s)/receptor(s) that ultimately stimulate the array of putative mTORC1 activators 
reviewed above.
MECHANOTRANSDUCTION AND THE REGULATION OF BONE MASS
Mechanoreception and tissue adaptation in bone: a different mechanism than muscle, 
involving division of labor among cell types
While skeletal muscle mass is ultimately determined by the net difference in the rates of 
protein degradation and protein synthesis within the cell, the regulation of bone mass 
represents a more complicated phenomenon because bone tissue is incapable of interstitial 
growth [130]. That is, the cross sectional size of a given muscle can change via hypertrophy 
or atrophy of preexisting myofibers, whereas cellular hypertrophy/atrophy of bone cells is 
not a mechanism that directly augments bone mass. In bone, changes in the mineralized 
matrix must be achieved by specialized cells (osteoblasts and osteoclasts) that are at the 
beck and call of the embedded master-regulatory cell type - the osteocyte [131]. Because 
changes in bone mass are enacted by the elaboration or removal of a complicated matrix, 
changes in bone mass occur much more slowly than the cell-trophic changes that occur in 
muscle tissue. Moreover, the physical environment of the osteocyte is completely different 
than that of bone cells localized on the bone surface. Osteocytes are entombed in a small, 
form-fitting cavity within the bone matrix (the lacuna). As the osteocyte cell processes 
emerge and course away from the cell body and lacuna, they travel in canaliculi (nano-
canals) within the bone matrix [132]. Decades ago, it was postulated that the osteocyte was 
the best candidate for a sensor cell type, for several reasons [133]. First, the osteocytes are 
regularly distributed throughout cortical and trabecular bone, even in areas of mineralized 
matrix devoid of vasculature. Consequently, the network of osteocytes provides a 
widespread load-monitoring “net” that infiltrates every cubic millimeter of bone tissue. 
Second, osteocytes are connected to one another, and to bone surface cells, through long 
cellular processes that course through the bone and project to the bone surfaces. Osteocytes 
have a large number of these cell processes (~50/cell) emanating from the cell body and 
coursing in all directions [134]. The cell processes join similar cell processes from 
neighboring osteocytes and transmit information inter-cellularly via gap junctions, which 
facilitate rapid cell-cell communication [135]. Third, it is clear that osteocytes are not 
effector cells, as they are entombed in a bony matrix and therefore are incapable of adding 
or removing very much matrix, and can only remove it in the small area surrounding their 
lacunae [136]. This very localized activity of osteocytes, while potentially meaningful for 
regulating serum calcium levels, has little to no effect on bone size, shape, and structural 
properties. Because their role as an effector cell is precluded, they have been thought of 
historically (somewhat by default) as a sensor cell [137]. Beyond teleological arguments, 
experiments have supported the role of the osteocyte as the primary mechanosensory cell 
type in bone. Interestingly, a recent gene expression profile conducted on purified, flow-
sorted populations of osteocytes extracted from living mouse bone, revealed a surprising 
number of highly expressed genes that are traditionally thought of as “muscle genes” [138]. 
While that experiment was not conducted under mechanically altered conditions, it is also 
worthwhile to consider that osteocytes might be more “muscle-like” than previously 
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thought, and that some of the mechanisms of strain sensation might overlap between these 
two cell types.
Ion Channels
Many mechanosensitive tissues in the body are regulated by ion channels. Ion channels are 
pore-forming proteins that traverse the plasma membrane and allow ions to flow into and 
out of a cell based on electrochemical gradient. Their activity (opening and closing) can be 
controlled by different mechanisms; among them are changes in voltage across the 
membrane, biochemical ligands, or physical stimuli such as mechanical perturbation of the 
membrane. It is well documented experimentally that ion channels play a crucial role in the 
process of mechanotransduction in bone [139, 140]. For example, Gd3+ is a potent blocking 
agent for mechanosensitive ion channels, and pretreatment of bone cells with Gd3+ prior to 
mechanical loading stimulation results in a loss of downstream mechanotransduction marker 
expression [141, 142]. However, Gd3+ is a fairly nonspecific inhibitor (e.g., some L-type 
voltage sensitive calcium channel inhibition has been reported), so it is difficult to be certain 
that the inhibitory effect of Gd3+ on mechanotransduction involves a mechanosensitive ion 
channel. More recently, the transient receptor potential (Trp) family of channels has been 
investigated regarding their role in bone cell mechanotransduction [143, 144]. Specifically, 
TrpV4, a receptor known to be sensitive to mechanical perturbation (most notably, cell 
swelling) and osmolarity in other tissues [145], was recently shown to modulate the 
response to mechanical disuse in mice. TrpV4 knockout mice subjected to tail suspension 
for 2 wk failed to lose bone and did not exhibit reduced bone formation rates, as was 
observed in tail suspended wild type mice [146]. The Trpv4 channel has been shown to be 
sensitive to shear stress in other cell types, thus its role in bone as a mechanosensor is 
promising. Another Trp channel that has received significant attention in bone cell 
mechanotransduction is TrpP1, also known as polycystin-1 (encoded by the Pkd1 gene). 
Several years ago, it was convincingly demonstrated that that polycystin-1 and polycystin-2 
regulate mechanotransduction in kidney epithelial cells [147]. Polycystin-1 and -2 reside 
largely on the primary cilium—a nonmotile ~250 nm thick cytoskeletal stalk that extends 
into the tubular lumen [148]. Deflection of the cilium from fluid movement in the renal 
tubules activates polycystin-1, which causes the polycystin-2 channel to open, kicking off a 
Ca2+ cascade that has multiple downstream effects [149]. For example, in osteocyte-specific 
polycystin-1 knockout mice, in vivo ulnar loading exhibited a ~70% reduction in load-
induced apposition rates compared to control mice, indicating that osteocytic polycystin-1 is 
an important protein in the anabolic response to skeletal loading [150]. Similar effects have 
been found in vitro, where cilium disruption via chemical treatment or gene silencing 
inhibits the response to matrix strain [151]. In light of the importance of fluid movement in 
the canaliculo-lacunar network, the primary cilium, and its compliment of associated 
proteins, is an attractive candidate for mechanosensing in the osteocytes. But it is difficult to 
envisage how the cilium would physically fit in the extracellular space because the distance 
between the canalicular wall and the osteocyte cell process/body is typically 50–80 nm and 
could be much smaller if measured on sections processed with newly refined fixation 
techniques that reduce cell shrinkage [152]. In summary, there is evidence suggesting that 
the primary cilium itself, or perhaps proteins normally associated with the cilium, mediate 
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mechanotransduction in bone; but greater experimentation in this area will be required to 
more fully understand the precise role of cilia in the mechanical signaling process.
G-protein coupled receptors
G-protein coupled receptors (GPCRs) represent the largest family of cell surface receptors, 
and are activated by a variety of ligands including neurotransmitters, hormones, small 
peptides, local cytokines, amino acids, and fatty acids, among others (reviewed in [153]). 
More than a decade ago, it was demonstrated that fluid flow activates G-proteins in 
osteoblasts, and that pharmacologically preventing G-protein activation prevents the normal 
response to fluid shear [154]. It is interesting to note that fluid shear stress leads to a 
conformational change in two GPCRs - the parathyroid hormone 1 receptor (PTH1R) and 
the B2 bradykinin receptor, in MC3T3 osteoblastic cells and BAEC endothelial cells [155, 
156]. This result was detected using GPCR conformation-sensitive fluorescence resonance 
energy transfer (FRET), which revealed conformational changes in these GPCRs occurring 
within milliseconds of shear exposure. The changes were independent of the presence of 
either receptor’s ligand. It was also reported that the responsiveness of the energy transfer 
signal could be modulated by membrane fluidity (e.g. modulation of membrane stiffness), 
indicating that these GPCRs might be direct sensors of mechanical perturbation of the 
membrane. While mechanotransduction may or may not involve either of these two 
particular receptors, the data make the larger point that other GPCRs, more crucial to the 
mechanotransduction response, might undergo similar conformational changes when the cell 
is mechanically stimulated. The premise that a ligand is not necessary for shear to activate 
intracellular G-proteins has been taken one step further, and it might be true that even the 
receptor itself is not necessary for shear-induced G-protein activation. For instance, the same 
group showed that when purified G-proteins are reconstituted into otherwise empty 
phospholipid vesicles, they could be activated (GDP hydrolysis) almost immediately upon 
fluid shear [157]. This flow-induced activation was independent of a GPCR presence, but 
rather, was modulated by membrane stiffness. Although, bone cells possess the G-protein 
machinery necessary to activate this pathway, verification of this mechanoreception 
mechanism in bone cells per se will require similar experiments in bone-specific models, 
which have not been done to date.
The search for the “mechanoreceptor” in bone is ongoing, with progress being made on 
several fronts. The molecule or mechanism that is at the forefront of mechanoreception—the 
protein that converts a physical signal into a biochemical signal—remains elusive. It is also 
possible that no single mechanism is responsible for initiating the entire event; numerous 
signaling systems in biology exhibit redundancy. While the mechanisms of signal reception 
are still being worked out, much greater progress has been made in the field of mechanically 
stimulated second messengers that are required for mechanically-induced changes in bone 
mass. Those mechanisms are described next.
Mechanically stimulated second messengers in bone
Once the mechanical signal is received by the local bone cell population and translated into 
an initial biological signal, a series of secondary biochemical signaling events must occur to 
propagate the signal within the cell and to other sensor/effector cells. Efforts to understand 
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the signaling pathways involved in mechanical signal propagation have uncovered a 
multitude of changes in the mechanically stimulated osteocyte/osteoblast, including gene 
expression changes, protein and lipid modifications (e.g., phosphorylation events), protein 
degradation, intracellular translocation events, release of secreted factors, and alterations in 
cell shape and size, among others. The challenge presented by these observations is to 
determine which among them are critical for mechanotransduction to occur, and which are 
simply auxiliary events that have few functional consequences for the mechanotransduction 
process.
Prostaglandins—One of the earliest pathways identified to be involved in bone cell 
mechanotransduction is the cyclooxygenase (Cox)/prostaglandin (PG) pathway. PGs are 
potent and short lived (sec/min) arachidonic acid (AA)-derived signaling molecules that act 
in a autocrine/paracrine manner [158]. In a multistep process, intracellular cyclooxygenase 
(Cox) enzymes convert AA to PGG2, and then to PGH2, after which various PG synthases 
generate specific PGs including PGE2 [158]. PGs are secreted from the cell in response to a 
number of stimuli where they can then bind to specific GPCRs. Vigorous jumping exercises 
in humans induce an immediate release of PGE2 from lower limb (loaded) bone tissue [159]. 
In rodents, mechanical loading up-regulates the mRNA and protein levels of Cox2 (the 
inducible isoform of Cox), whereas the constitutive isoform (Cox1) remains unchanged 
[160, 161]. The importance of PGE2 signaling has been demonstrated in vivo by depleting 
the intracellular PGE2 pool prior to mechanical loading. Pharmacologic inhibition of both 
Cox1 and Cox2 via indomethacin treatment, or selective inhibition of Cox2 alone via 
NS-398 treatment, was found to reduce osteogenic response to loading conducted several 
hours after administration of the inhibitors [162]. This result has been confirmed in vitro 
using fluid shear and stretch, where PGE2 levels can more easily be measured from cell 
culture media [163–165]. The mechanism of PGE2 release from mechanically stimulated 
cells is controversial, and might involve the opening of large, pore-forming connexin-43 
hemichannels [166] or the purinergic P2X7 protein complex [167, 168]. Once released, 
PGE2 binds in an autocrine or paracrine fashion to the heptahelical Ep receptors (Ep1-4), 
which mediate its effects [169, 170]. In summary, both in vivo and in vitro experiments 
point to a prominent role for prostaglandins in bone cell mechanotransduction, but the 
mechanism by which PGE2 is released, and which receptors are important for its paracrine/
autocrine effects, are unclear.
Wnt signaling—More recently, the Wnt (Wingless-related integration site) signaling 
pathway has been identified as a major intermediate player in bone cell 
mechanotransduction [171]. The Wnt family of secreted glycoproteins is made up of 19 
different Wnt genes (in humans) whose protein products can activate multiple signaling 
pathways (reviewed in [172]). Canonical Wnt signaling involves secreted Wnts activating a 
receptor complex comprising a single-pass low-density lipoprotein receptor-related protein 
(Lrp) and a heptahelical Frizzled (Fzd) receptor which subsequently leads to the activation 
of the Dishevelled (Dsh) phosphoprotein [173]. Activated Dsh inhibits GSK3β activity 
which, in turn, results in reduced GSK3β-mediated phosphorylation of the transcription 
factor β-catenin and thus reduced β-catenin degradation [173]. This allows the stabilized β-
catenin to act as a transcriptional co-activator by forming complexes with members of the 
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TCF/LEF family of transcription factors and increasing the expression of various Wnt/β-
catenin target genes [173]. Importantly, numerous target genes of β-catenin are associated 
with enhanced osteogenesis and reduced resorption. Using a reporter construct, mechanical 
loading was shown to activate β-catenin mediated transcription both in vivo and in vitro 
[174, 175]. Remarkably, osteocytes appear to be the first cells to exhibit activated β-catenin 
transcriptional activity after loading [176], suggesting that Wnt signaling in osteocytes 
might be a sensor cell response pathway. Moreover, deletion of one of the canonical Wnt co-
receptors-Lrp5-in mice appears to prevent load-induced bone formation [177, 178], which 
suggests that Lrp5/β-catenin signaling is vitally important for mechanotransduction in bone. 
The canonical Wnt pathway is negatively regulated by a number of endogenous secreted 
inhibitors that bind Lrp5/6 or Wnts. Among these inhibitors is a potent Lrp5/6 antagonist-
sclerostin-that is highly expressed by mature osteocytes but not by other bone cells (e.g., 
osteoblasts, osteoclasts, bone lining cells). Sclerostin, the protein product of the SOST gene, 
is significantly down-regulated by mechanical loading, and significantly up-regulated by 
mechanical disuse [179]. Forced overexpression of a SOST transgene prevents load-induced 
bone formation [180], whereas Sost deletion improves mechanotransduction [181]. 
Moreover, inhibition of Sost during mechanical disuse prevents bone loss [182] In summary, 
Wnt has been identified as a major mediator of bone cell mechanotransduction. The 
modulation of numerous secreted Wnt inhibitors, as well as the downstream signaling nodes 
activated by Wnt, are still being defined.
IGF-1 signaling—Unlike skeletal muscle, in which IGF-1 does not appear to be necessary 
for the mechanically-induced increase in mTORC1 signaling and skeletal muscle mass, bone 
cell mechanotransduction requires IGF-1 signaling for the anabolic effects of loading. For 
instance, IGF-1 is known to play an essential role in embryonic bone development [183, 
184] and early studies also suggested a potential role for IGF-1 in the regulation of bone 
mass in response to changes in mechanical loading. Specifically, studies conducted in 
mechanically stimulated osteocytes in vitro, and in mechanically stimulated rat vertebrae 
and tibia in vivo, revealed increased expression of IGF-1 mRNA expression after a bout of 
increased loading [185–187]. Furthermore, it was shown IGF-1 administration increases 
osteoblast proliferation in vivo [188] and that transgenic overexpression of IGF-1 in 
osteoblasts resulted in enhanced responsiveness to in vivo mechanical loading in mice [189]. 
Moreover, conditional disruption of the IGF-1 gene in type 1α(2) collagen-expressing cells 
in vivo effectively eliminated the osteogenic responses to increased mechanical loading in 
mice [190]. More recently, conditional osteocyte knockout of IGF-1 also ablated the 
osteogenic response to mechanical loading and this occurred despite normal IGF-1 
expression in osteoblasts [191]. In reloading models, recombinant IGF-1 infusion has been 
shown to be sufficient to enhance the differentiation of osteoblast precursor cells and 
increase trabecular bone formation in rats subjected to mechanical unloading [192], while 
osteocyte IGF-1 receptor expression was found to be necessary for reloading-induced 
periosteal bone formation in mice [193]. Combined, these data suggest that IGF-1 does 
indeed play a critical role in the mechanical regulation of bone mass. However, the 
downstream effectors of activated IGF-1 are less clear. For instance, in vitro IGF-I treatment 
stimulates the activation of the IGF-1 receptor, Ras, ERK1/2 and Akt in cultured BMOp 
cells isolated from normally loaded bones [188], but the downstream targets of these 
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signaling events is unknown. In another study, conditional knockout of osteocyte IGF-1 
reduced the load-induced increase in Wnt signaling-related gene expression and β-catenin 
protein levels. It also increased the loading-induced expression of the SOST gene and 
inhibited the load-induced increase in Cox-2 expression [191]. In summary, the IGF-1 axis 
is clearly important for mechanical signaling in bone cells, with more limited evidence 
suggesting that IGF-1 may regulate Wnt and PG signaling in response to increased 
mechanical loading. More studies are needed, however, to further investigate other possible 
IGF-1 mediated signaling pathways (e.g. Ras/ERK and Akt signaling).
Nitric oxide signaling—Similar to skeletal muscle, another pathway activated by 
mechanical stimulation in bone is nitric oxide signaling [194]. Nitric oxide (NO) is a free 
radical and as such can diffuse through the plasma membrane freely. NO is generated from 
the amino acid L-arginine by one of three isoforms of Nitric Oxide Synthase (NOS). In 
vitro, NO is released from mechanically stimulated osteoblasts and osteocytes [195–197]. In 
vivo, depletion of the NO pool prior to mechanical loading in rats using one of several NOS 
inhibitors significantly impairs the osteogenic response to loading [198]. Moreover, in mice 
lacking the inducible form of NOS (iNOS−/−), a return to normal cage floor locomotion 
following 7 days of tail suspension failed to generate an otherwise osteogenic response, as 
was seen in iNOS replete mice [199]. These experiments suggest that the osteoblastic 
response to mechanical stimulation requires NO signaling. Perhaps equally noteworthy is 
the effect that NO signaling has on bone resorption. In addition to enhancing bone 
formation, mechanical loading impairs bone resorption and NO signaling might be one of 
the main mechanisms by which it is accomplished. For instance, mechanically-induced 
increases in NO cause a decrease in RankL which is a major regulator of osteoclast 
development and survival [200]. In summary, while NO appears to be an important second 
messenger in bone cell mechanotransduction, its target enzymes and cell type of origin (i.e., 
stromal cells, osteocytes, lining cells) are still open to investigation.
In conclusion, numerous second messenger cascades are activated in bone tissue during and 
after mechanical stimulation, including IGF-1, prostaglandins, nitric oxide, and components 
of the Wnt pathway. How these various cascades interact with one another is unclear. 
Recent experimental work has begun to link some of these otherwise disparate pathways 
together. For example, Kitase et al [201] have shown that mechanically induced PGE2 in 
osteocytes participates in an autocrine loop that ultimately inactivated GSK3β and stimulates 
the downstream canonical Wnt target β-catenin. It remains to be determined whether other 
major cascades in bone cell mechanotransduction are linked, or whether they act as 
accessory pathways in the event that one is impaired. The need for clear delineation of the 
processes involved is obvious: recapitulation of the mechanotransduction cascades using 
non-mechanical stimuli holds great promise in preventing fractures, particularly in those 
with frail skeletons that could not endure significant loading episodes.
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SIMILARITIES AND DIFFERENCES BEWTEEN SKELETAL MUSCLE AND 
BONE
While the differences in mechanotransduction mechanisms between skeletal muscle and 
bone appear to be great, there is also evidence that some common mechanisms might exist. 
For example, recent studies suggest that mechanically sensitive ion channels, such as TrpP1 
channels in bone and TrpV1channels in skeletal muscle, may play significant roles in the 
anabolic response to increased mechanical loading. Moreover, a role for these mechanically 
sensitive ion channels suggests that ions, such as Ca2+, may be an important second 
messenger in both of these tissues. In addition, NO, albeit from potentially different sources 
(iNOS in bone and nNOS in skeletal muscle), also appears to be involved in load-induced 
increases in bone and skeletal muscle mass. However, there are also mechanically sensitive 
mechanisms that are established in one tissue but remain to be convincingly demonstrated in 
the other tissue (see Table 1). For example, as described above, it has been convincingly 
shown that mTORC1 signaling plays a fundamental role in mechanically-induced increases 
in skeletal muscle mass; however, its role in bone mechanotransduction remains to be 
determined. Furthermore, there is compelling evidence that PG and Wnt signaling are 
mechanically sensitive in bone and that they play important roles in load-induced increases 
in bone mass; but whether these molecules play a role in the mechanical regulation of 
skeletal muscle mass remains unclear. Therefore, in the hope of stimulating new research 
into these questions we briefly review the evidence for a potential role for PG and/or Wnt 
signaling in the mechanical regulation of skeletal muscle mass, and for a potential role of 
mTORC1 signaling in the mechanical regulation of bone mass.
A Role for Prostaglandins in the Mechanical Regulation of Skeletal Muscle Mass?
PGs are known to be produced in skeletal muscle and incubation with AA or PGF2α has 
been shown to stimulate an increase in protein synthesis in isolated skeletal muscles and to 
induce hypertrophy of cultured myotubes [202–207]. Moreover, the PGF2α-induced 
myotube hypertrophy was recently shown to mediated through a PI3K/ERK/mTORC1-
dependent mechanism [204]. Importantly, numerous studies have shown that mechanical 
stimulation of skeletal muscle induces an increase in PGs, including PGF2α (for reviews see 
[208, 209]). Thus, an increase in PG synthesis and secretion could play a role in the 
mechanically activation of mTORC1, protein synthesis and muscle hypertrophy. Indeed, 
high doses of the general COX inhibitors, acetaminophen and ibuprofen, have been shown 
to be sufficient to inhibit the increase in protein synthesis that occurs following eccentric 
exercise in humans [210]. In contrast, ‘over-the-counter’ doses of general COX inhibitors do 
not inhibit resistance training-induced increases in muscle mass [208]. Furthermore, a 
COX-2 isoform specific inhibitor (NS398) has been shown to blunt synergist ablation-
induced muscle hypertrophy in mice without inhibiting the activation of mTORC1 signaling 
[211]. Finally, not all PGs stimulate protein synthesis. For example, PGE2 (and AA) 
stimulates protein degradation in skeletal muscle [203]. These disparate findings highlight 
the need for more studies, using a range of experimental models, to clarify the role of 
different PGs in the mechanical regulation of protein turnover and skeletal muscle mass. 
Moreover, given the current evidence that PI3K and ERK signaling are not required for the 
mechanical activation of mTORC1 signaling, this would suggest that the role of PGs in the 
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mechanical regulation of skeletal muscle mass may be exerted through an mTORC1-
independent mechanism.
A Role for Wnt Signaling in the Mechanical Regulation of Skeletal Muscle Mass?
Wnt molecules play critical roles in the embryonic development of skeletal muscle and in 
the regulation skeletal muscle regeneration [212, 213]. Importantly, acute maximal exercise 
has been shown to increase Dsh/GSK3β interaction, and decrease GSK3β activity and β-
catenin phosphorylation in humans [214]. Furthermore, resistance training-induced muscle 
fiber hypertrophy is associated with an increased expression of various Wnt signaling 
pathway members (e.g. Wnt1, β-catenin, LEF1, Cyclin D1) [215]. In mice, chronic 
mechanical overload-induced muscle hypertrophy is associated with an increase in β-
catenin, Fzd-1, DSH-1 and LEF-1 protein expression, increased nuclear abundance of β-
catenin and LEF-1, and increased expression of Wnt/β-catenin target genes c-myc and cyclin 
D1 [216]. Moreover, β-catenin has been shown to be necessary for chronic overload-induced 
muscle fiber hypertrophy [217]. Thus, current evidence strongly suggests that canonical 
Wnt/β-catenin signaling plays a significant role in mechanically-induced skeletal muscle 
growth. More recently, evidence has also demonstrated a link between Wnt signaling, 
muscle hypertrophy and the activation of mTORC1 signaling [218, 219]. Specifically, the 
overexpression of Wnt7a (but not Wnt 3a or 5a) induced hypertrophy of muscle fibers in 
vivo, and in myotubes that was independent of myoblast cell proliferation, differentiation 
and fusion [218]. This Wnt7a-induced hypertrophy was found to be associated with a non-
canonical Wnt activated signaling pathway that required Fzd7 and G protein subunit αs, and 
involved the activation of PI3K/Akt/mTORC1 signaling, independent of the IGF-1 receptor 
or IRS1 activation [218]. Moreover, Wnt7a-induced myotube hypertrophy was inhibited by 
rapamycin [218]. Overall, there is significant data implicating canonical Wnt signaling in 
the mechanical regulation of skeletal muscle mass, while more recent data suggests a 
possible role for non-canonical Wnt signaling in the activation of mTORC1 signaling. 
However, while it is tempting to speculate that the non-canonical Wnt signaling-induced 
activation of mTORC1 could potentially play a role in the mechanical activation of protein 
synthesis and skeletal muscle hypertrophy, several important questions remain to be 
answered. For example, are Wnt7a expression and/or secretion increased during or after 
different types of acute and chronic mechanical stimulation? Given the current evidence that 
the acute mechanical activation of mTORC1 occurs in a PI3K/Akt-independent manner, 
perhaps a Wnt7a could contribute to the more delayed (hours) activation of mTORC1. If so, 
what is the cellular origin of the secreted Wnt7a: skeletal muscle cells, cells of the extra 
cellular matrix and/or immune cells? Thus, while promising, significantly more work is 
required to establish a role, if any, for non-canonical Wnt signaling in the mechanical 
activation of mTORC1, protein synthesis and skeletal muscle growth.
A Role for mTORC1 in the Mechanical Regulation of Bone Mass?
Given the predominant role that mTORC1 signaling plays in mechanically-induced skeletal 
muscle growth, it is of interest to examine whether there is any evidence for a similar role 
for mTORC1 in the mechanical regulation of bone mass. To date, there is some evidence 
that mTORC1 does indeed play a role in bone growth and, more specifically, in the 
regulation of long bone length. For example, several studies have shown that the mTORC1 
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inhibitor, rapamycin, inhibits long bone growth in young rodents, possibly by directly 
inhibiting chondrocyte differentiation and/or indirectly by inhibiting growth plate 
angiogenesis which leads to reduced chondrogenesis [220–224]. Thus, mTORC1 may play a 
vital role in long bone growth providing a mechanism for mitogens and nutrients to 
stimulate bone growth via increased growth plate activity. Importantly, recent evidence also 
implicates mTORC1 in mechanically-induced cartilage growth [225]. Specifically, the 
mechanical activation of mTORC1 was found to be necessary for cell proliferation, 
chondrogenesis, and cartilage growth during embryonic bone development [225]. Other 
evidence suggests that mTORC1 not only regulates chondrocytes, but also regulates 
osteoblasts. For instance, rapamycin has been shown to inhibit the proliferation and 
differentiation of preosteoblastic cells, in part, by inhibiting the expression of cyclins A and 
D1, and the transcription factor Runx2, respectively [226]. Furthermore, rapamycin has also 
been reported to inhibit erythropoietin-induced osteoblast differentiation in some 
preosteoblastic cell lines [227]. These data suggest that mTORC1 could play an important 
role on regulating bone mass, in part, by modulating the abundance of osteoblasts. This is 
further supported by a recent study that implicated mTORC1 in a Wnt signaling pathway 
that enhances post-natal bone mass via an increase in osteoblast numbers and activity [228]. 
Specifically, in this study, the induction of Wnt7b expression, either during embryonic 
development or at 4 wk post-natal, resulted in profound increases in bone mass that were 
related to increased osteoblast numbers [228]. Furthermore, it was found that Wnt7b (and 
Wnt3a) activated mTORC1 signaling, in vitro and in vivo, via a non-canonical PI3K/Akt 
pathway, and that the inducible deletion of the mTORC1 component, Raptor, markedly 
reduced the Wnt7b-induced increase in osteoblast activity and bone mass [228]. 
Interestingly, rapamycin analogs (e.g., evirolimus) appear to inhibit osteoclast survival and 
activity, suggesting that the activation of mTORC1 might also increase bone resorption 
[229]; however, the Wnt7b-induced increase in mTORC1 signaling and bone mass was not 
associated with changes in bone resorption [228]. These exciting data suggest that the 
activation of mTORC1 may indeed play a role in the regulation of bone mass by stimulating 
an increase in osteoblast numbers and activity.
In summary, an expanding body of evidence suggests that mTORC1 plays an important role 
in promoting long bone growth by increasing chondrocyte proliferation and growth plate 
activity. Importantly, mTORC1 has also been shown to promote increases in developmental 
and post-natal bone mass by stimulating an increase in osteoblast proliferation, 
differentiation and activity; however, there is currently no direct evidence linking mTORC1 
signaling with mechanically-induced increases in osteoblast function and bone mass. 
Nevertheless, given the evidence that Wnt signaling plays a major role in 
mechanotransduction in bone, and the recent finding that Wnt7a is sufficient to increase 
bone mass via an mTORC1-depenent mechanism, future research may lead to the 
establishment of mTORC1 as a bona fide regulator of mechanically-induced increases in 
bone mass.
CONCLUSION
In conclusion, the molecular mechanisms that regulate mechanotransduction in skeletal 
muscle and bone are complex, with multiple mechanisms likely operating in synergy. In 
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skeletal muscle mTORC1 has been established as a central mediator of mechanically-
induced changes in protein synthesis and muscle cell size, with several putative candidates 
proposed to play a role in mTORC1’s activation (e.g. PA, amino acids, TSC2 translocation, 
Ca2+ and NO). However, despite these advances, still very little is known about the 
upstream mechanically-activated sensor(s) that ultimately trigger these second messengers 
to promote mTORC1 signaling. In bone, a much more complicated picture of 
mechanotransduction has emerged with the necessity to consider the role of multiple cell 
types in this process. Nonetheless, current evidence has shown that mechanically-sensitive 
ion channels and G-protein coupled receptors play significant roles in detecting changes in 
mechanical stress in bone mass. Furthermore, IGF-1, NO, PG and Wnt signaling have all 
been implicated as second messengers in bone mechanotransduction. Major questions that 
remain to be resolved include whether PG and non-canonical Wnt signaling plays a role in 
the mechanical activation of mTORC1 in skeletal muscle and whether mTORC1 signaling is 
involved in bone mechanotransduction. This review highlights that there is still much be 
discovered about the process of mechanotransduction in skeletal muscle and bone. By 
examining the differences and similarities in mechanotransduction between these two tissues 
it is hoped that this review will stimulate new insights and ideas for future research and 
collaboration between bone and muscle biologists. Ultimately, advances in our knowledge 
of the mechanisms of mechanotransduction will assist in the development of effective 
exercise and pharmaceutical strategies aimed at increasing, and/or preventing the loss of, 
bone and skeletal muscle mass.
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ABBREVIATIONS
AA arachidonic acid
Akt v-Akt Murine Thymoma Viral Oncogene
BAPTA-AM 1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 
tetrakis(acetoxymethyl ester)
CaMKKα Ca2+/calmodulin-dependent protein kinase alpha
Cox cyclooxygenase
DGK diacylglycerol kinase
DGKζ diacylglycerol kinase zeta
Dsh Dishevelled
ERK extracellular signal-regulated kinase
FRB FKBP12-rapamycin binding
FRET fluorescence resonance energy transfer
Fzd Frizzled
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GAP GTPase activating protein
Gd3+ gadolinium
GDP guanosine diphosphate
GPCR G-protein coupled receptor
GSK3β glycogen synthase kinase 3 beta
GTP Guanosine-5'-triphosphate
H2O2 hydrogen peroxide
IGF-1 insulin-like growth factor 1
iNOS inducible nitric oxide synthase
LEF Lymphoid enhancer-binding factor
LEL late endosomal/lysosomal
L-NAME L-NG-Nitroarginine methyl ester
LPAATθ lysophosphatidic acid acyltransferase theta
Lrp lipoprotein receptor-related protein
MAPK mitogen-activated protein kinase
MEK Mitogen/Extracellular signal-regulated Kinase
MGF mechano growth factor
mTOR mechanistic or mammalian target of rapamycin
mTORC1 mTOR complex1
mTORC2 mTOR complex2
NO nitric oxide
NOS nitric oxide synthase
nNOS neuronal nitric oxide synthase
Nox4 NADPH oxidase 4
O2− superoxide
ONOO− peroxynitrite
p90RSK 90 kDa ribosomal S6 kinase
PA, PDL1 phospholipase D1; phosphatidic acid
PG prostaglandin
PI3K phosphatidylinositide 3-kinase
Pkd polycystic kidney disease
PTH1R parathyroid hormone 1 receptor
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RAF rapidly accelerated fibrosarcoma
RANKL Receptor activator of nuclear factor kappa-B ligand
RAS rat sarcoma oncogene
Rheb Ras homologue enriched in the brain
RNS reactive nitrogen species
ROS reactive oxygen species
RUNX2 Runt-related transcription factor 2
SR sarcoplasmic reticulum
SC satellite cells
TCF T-cell factor
Trp transient receptor potential
TrpV1 transient receptor potential cation channel subfamily V1
TrpV4 transient receptor potential cation channel subfamily V4
TSC2 Tuberous Sclerosis Complex 2
Vps34 vacuolar protein sorting 34
Wnt, Wnt Wingless-related integration site.
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Highlights
• We review the primary molecular mechanisms that have been implicated in 
skeletal muscle and bone mechanotransduction.
• mTORC1 signaling plays a fundamental role in the mechanical regulation of 
skeletal muscle mass and has several putative activators.
• GPCRs, ion channels, prostaglandins, IGF-1, Wnts and NO play roles in bone 
mechanostransduction.
• It remains to be determined whether mTORC1 signaling plays a role in the 
mechanical regulation of bone mass.
• It remains unknown whether prostaglandins and/or Wnts play a role in the 
mechanical activation of mTORC1 in skeletal muscle.
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Table 1
Summary of the pathways/molecules involved in muscle and/or bone mechanotransduction1,2
Muscle Bone
mTORC1 ✓✓✓
IGF-1 ✓ ✓✓
Erk1/2 ✓ ✓✓
PA ✓✓
TSC2/Rheb ✓
iCa2+ ✓ ✓✓✓
ROS/RNS ✓ ✓✓
AA ✓
GPCRs ✓
PGs ✓ ✓✓
Wnt ✓ ✓✓✓
1
the number of check marks indicate the strength of the role in mechanotransduction (based on the literature).
2
see text for full names of abbreviated molecules
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